GU Cancers 2020 | Nivolumab with ipilimumab for mRCC

Tian Zhang

Tian Zhang, MD, Duke Cancer Center, Durham, NC, discusses the follow-up results from the Checkmate 214 (NCT02231749) and PDIGREE (NCT03793166) studies, which look at nivolumab combined with ipilimumab as a treatment for patients with metastatic renal cell carcinoma (mRCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter